A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
- 1 August 2004
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 22 (3) , 263-275
- https://doi.org/10.1023/b:drug.0000026252.86842.e2
Abstract
Purpose:To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal lurtotecan, OSI-211 (formerly known as NX211), given as a short...Keywords
This publication has 15 references indexed in Scilit:
- Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic ToxicityJournal of Clinical Oncology, 2002
- Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing miceAnti-Cancer Drugs, 2001
- DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 2000
- Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.2000
- Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.2000
- Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG)Annals of Oncology, 2000
- Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomesPublished by Elsevier ,1998
- 528: A phase II study with Gl147211 in ovarian cancerEuropean Journal Of Cancer, 1997
- 928 Phase I trial of the topoisomerase I inhibitor GG211 as a 72-hour infusionEuropean Journal Of Cancer, 1995
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993